| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19dbd05e752c4bdcc42a64b8e1b19230 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-50 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2005-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83898538c997439d00aedbe561565d09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e031772e46665f6c982b6fcbe5628e2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5d543767c650325cd89b062c93ab103 |
| publicationDate |
2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006140909-A1 |
| titleOfInvention |
Method of using adenoviral vectors with increased persistence in vivo |
| abstract |
The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours post-administration is at least about 1%. Alternatively, the normalized average bloodstream concentration over 24 hours post-administration is at least about 5-fold greater than the normalized average bloodstream concentration for an equivalent dose of a wild-type adenoviral vector. A method of destroying tumor cells in a mammal also is provided, as is a replication-deficient adenoviral vector comprising a serotype 5 or serotype 35 adenoviral genome with a serotype 41 fiber protein, wherein the replication-deficient adenoviral vector exhibits reduced native binding to integrins. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11439678-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849945-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10548929-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10322152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11173186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016120922-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000559-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155622-B2 |
| priorityDate |
2003-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |